Subacute L-DOPA in mice: biochemical and behavioural effects

Area of Science:

• Neuroscience
• Pharmacology
• Animal Behavior

Background:

• Levodopa (L-DOPA) is a primary treatment for Parkinson's disease, often combined with a peripheral decarboxylase inhibitor like benserazide.
• Understanding the neuropharmacological mechanisms behind L-DOPA's efficacy and potential for enhanced response is crucial for optimizing treatment.
• Previous studies suggest complex interactions between L-DOPA, benserazide, and central dopamine pathways.

Purpose of the Study:

• To investigate the neuropharmacological basis for enhanced locomotor stimulation following repeated oral administration of L-DOPA plus benserazide in mice.
• To determine if the enhanced response is related to central dopamine receptor sensitivity changes or altered drug metabolism.
• To elucidate the role of dopamine (DA) receptor stimulation in mediating the observed behavioral effects.

Main Methods:

• Mice were pretreated with L-DOPA (200 mg/kg) plus benserazide (50 mg/kg) or vehicle, then challenged 24 hours later with the same combination.
• Locomotor activity was measured to assess stimulation.
• Dopamine receptor sensitivity was evaluated using apomorphine challenge doses.
• Antagonism studies were performed using haloperidol or pimozide.
• Brain levels of L-DOPA and dopamine were quantified after drug challenge.

Main Results:

• Pretreatment with L-DOPA plus benserazide resulted in significantly greater locomotor stimulation compared to vehicle pretreatment.
• The enhanced response was not attributed to benserazide alone or altered central dopamine receptor sensitivity.
• The effect was dependent on dopamine receptor stimulation, as it was antagonized by haloperidol and pimozide.
• Pretreated animals exhibited significantly higher brain levels of L-DOPA and dopamine following the challenge dose.

Conclusions:

• The enhanced locomotor response to repeated L-DOPA plus benserazide administration is mediated by dopamine receptor stimulation.
• This phenomenon appears to be dependent on mechanisms that increase brain concentrations of L-DOPA and consequently dopamine.
• The findings suggest that prior exposure to the L-DOPA-benserazide combination can potentiate its own behavioral effects through altered pharmacokinetics or pharmacodynamics.